astemizole has been researched along with EHS Tumor in 1 studies
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.
astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurokawa, M | 1 |
| Futamura, Y | 1 |
| Obata, M | 1 |
| Shibutani, Y | 1 |
1 other study available for astemizole and EHS Tumor
| Article | Year |
|---|---|
Re: Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates.
Topics: Animals; Astemizole; Bromodeoxyuridine; Fibrosarcoma; Histamine H1 Antagonists; Melanoma, Experiment | 1995 |